Du är här
2022-12-06
Redeye: Redeye Initiates Coverage of Enzymatica
Redeye initiates coverage of Enzymatica, a Swedish commercial-stage medtech company offering ColdZyme for treating, alleviating, and shortening the duration of a cold. Its establishment in the Swedish market, followed by an ongoing global expansion with well-known distribution partners, offers a compelling case, where we expect a sales CAGR of 59% between 2022-2026e.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments